The anti-ischemic and anti-anginal properties of statins

Current Atherosclerosis Reports

Volumn 13, Issue 1, 2011, Pages 43-50

  Lardizabal, Joel A ^a   Deedwania, Prakash C ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angina pectoris; Cardiovascular disease; Coronary heart disease; Lipid lowering; Myocardial ischemia; Statin

Indexed keywords

AMLODIPINE; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VITAMIN;

ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW FAT DIET; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PUBLIC HEALTH PROBLEM; REPERFUSION INJURY; SINGLE DRUG DOSE; SURVIVAL RATE; VASODILATATION;

ANGINA PECTORIS; ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPOPROTEINS, LDL; MYOCARDIAL ISCHEMIA; PLAQUE, ATHEROSCLEROTIC; REPERFUSION INJURY; TREATMENT OUTCOME; VASODILATION;

EID: 79551516177     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0147-y     Document Type: Article

References (45)

1. American Heart Association Statistics Committee and Stroke Statistics Subcommittee 2010 Executive Summary: Heart Disease and Stroke Statistics-2010 Update: A Report From the American Heart Association Circulation 121 7 948 954 10.1161/CIRCULATIONAHA.109.192666
2. S Stewart NF Murphy A Walker, et al. 2003 The current cost of angina pectoris to the National Health Service in the UK Heart 89 8 848 853 1:STN:280:DC%2BD3szjtVOrug%3D%3D 10.1136/heart.89.8.848 12860855
3. PC Deedwania EV Carbajal VR Bobba 2007 Trials and tribulations associated with angina and traditional therapeutic approaches Clin Cardiol 30 2 Suppl 1 I16 I24 10.1002/clc.20049 18373326
4. In: The AHA guidelines and scientific statements handbook. Ed. by V. Fuster. © 2009 American Heart Association.
5. BARI 2D Study Group 2009 A randomized trial of therapies for type 2 diabetes and coronary artery disease N Engl J Med 360 24 2503 2515 10.1056/NEJMoa0805796 This study showed that optimal medical therapy is comparable to a strategy of prompt revascularization in the initial management of diabetic patients with chronic stable angina
6. EJ Mills B Rachlis P Wu PJ Devereaux P Arora D Perri 2008 Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65, 000 patients J Am Coll Cardiol 52 22 1769 1781 1:CAS:528:DC%2BD1cXhsVWht7jE 10.1016/j.jacc.2008.08.039 19022156
7. TJ Wilt HE Bloomfield R MacDonald, et al. 2004 Effectiveness of statin therapy in adults with coronary heart disease Arch Intern Med 164 13 1427 1436 1:CAS:528:DC%2BD2cXmsVKqsb0%3D 10.1001/archinte.164.13.1427 15249352 (Pubitemid 38937854)
8. AJ van Boven JW Jukema AH Zwinderman, et al. 1996 Reduction of Transient Myocardial Ischemia With Pravastatin in Addition to the Conventional Treatment in Patients With Angina Pectoris Circ 94 1503 1505
9. PH Stone DM Lloyd-Jones S Kinlay, et al. 2005 Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study Circulation 111 14 1747 1755 1:CAS:528:DC%2BD2MXivFeltbY%3D 10.1161/01.CIR.0000160866.90148. 76 15809368 (Pubitemid 40525138)
10. P Deedwania PH Stone CN Bairey Merz, et al. 2007 Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) Circ 115 6 700 707 1:CAS:528:DC%2BD2sXhtlGqtbs%3D 10.1161/ CIRCULATIONAHA.106.654756 (Pubitemid 46294760)
11. TR Pedersen J Kjekshus K Pyörälä, et al. 1998 Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S) Am J Cardiol 81 3 333 335 1:CAS:528:DyaK1cXhtFWltro%3D 10.1016/S0002-9149(97)00904-1 9468077 (Pubitemid 28099310)
12. WR Aengevaeren GJ Uijen JW Jukema, et al. 1997 Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS) Circulation 96 2 429 435 1:CAS:528:DyaK2sXltlShtbY%3D 9244208
13. Deanfield JE, Selleir P, Thaulow E, et al. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Hrt J. 2010 [Epub].
14. B Pitt D Waters WV Brown, et al. 1999 Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators N Engl J Med 341 2 70 76 1:CAS:528:DyaK1MXks1Glsb4%3D 10.1056/NEJM199907083410202 10395630 (Pubitemid 29314237)
15. The INSPIRE Investigators 2006 An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction J Am Coll Cardiol 48 12 2458 2467 10.1016/j.jacc.2006.07.068 (Pubitemid 44881230)
16. COURAGE Trial Research Group 2007 Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 15 1503 1516 10.1056/NEJMoa070829 (Pubitemid 46588415)
17. V Fuster PR Moreno ZA Fayad R Corti JJ Badimon 2005 Atherothrombosis and high-risk plaque: part I: evolving concepts J Am Coll Cardiol 46 6 937 954 10.1016/j.jacc.2005.03.074 16168274 (Pubitemid 41316498)
18. M Navab GM Ananthramaiah ST Reddy, et al. 2004 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J Lipid Res 45 6 993 1007 1:CAS:528:DC%2BD2cXksFCksbk%3D 10.1194/jlr.R400001-JLR200 15060092 (Pubitemid 38679495)
19. A Saiki T Murano F Watanabe, et al. 2005 Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes J Atheroscler Thromb 12 3 163 168 1:CAS:528:DC%2BD28XnvVyrsbc%3D 16020917
20. PH Jones MH Davidson EA Stein, et al. 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 92 2 152 160 1:CAS:528:DC%2BD3sXlt1Wmsb8%3D 10.1016/S0002-9149(03)00530-7 12860216 (Pubitemid 36835963)
21. M Yano T Matsumura T Senokuchi, et al. 2007 Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages Circ Res 100 10 1442 1451 1:CAS:528: DC%2BD2sXltl2ntr4%3D 10.1161/01.RES.0000268411.49545.9c 17463321 (Pubitemid 46834756)
22. JR Crouse 3rd JS Raichlen WA Riley, et al. 2007 Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial JAMA 297 12 1344 1353 1:CAS:528:DC%2BD2sXjs1ejtLw%3D 10.1001/jama.297.12.1344 17384434 (Pubitemid 46513235)
23. ML Bots MK Palmer S Dogan, et al. 2009 Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study J Intern Med 265 6 698 707 1:CAS:528:DC%2BD1MXnslKrt70%3D 10.1111/j.1365-2796.2009.02073.x 19298496
24. SE Nissen SJ Nicholls I Sipahi, et al. 2006 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 13 1556 1565 1:CAS:528:DC%2BD28Xjt12itrc%3D 10.1001/jama.295.13. jpc60002 16533939
25. BG Brown XQ Zhao DE Sacco JJ Albers 1993 Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease Circulation 87 6 1781 1791 1:CAS:528: DyaK3sXms1Wrsbo%3D 8504494
26. M Crisby G Nordin-Fredriksson PK Shah, et al. 2001 Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 7 926 933 1:CAS:528:DC%2BD3MXit1Cru70%3D 11181465
27. PO Bonetti SH Wilson M Rodriguez-Porcel, et al. 2002 Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering J Am Coll Cardiol 40 3 546 554 1:CAS:528:DC%2BD38Xms1aitrY%3D 10.1016/S0735-1097(02)01985- X 12142124 (Pubitemid 34833173)
28. JM Mostaza MV Gomez F Gallardo, et al. 2000 Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels J Am Coll Cardiol 35 1 76 82 1:CAS:528:DC%2BD3cXptlehuw%3D%3D 10.1016/S0735-1097(99)00529-X 10636263 (Pubitemid 30061263)
29. RG Schwartz TA Pearson VG Kalaria, et al. 2003 Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial J Am Coll Cardiol 42 4 600 610 1:CAS:528:DC%2BD3sXnsFerur0%3D 10.1016/S0735-1097(03)00767-8 12932588 (Pubitemid 37000172)
30. JM McLenachan JK Williams RD Fish, et al. 1991 Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis Circulation 84 3 1273 1278 1:STN:280:DyaK3Mzls1Kntw%3D%3D 1884452
31. H Omori H Nagashima Y Tsurumi, et al. 2002 Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects Br J Clin Pharmacol 54 4 395 399 1:CAS:528:DC%2BD38XpsVWitLw%3D 10.1046/j.1365-2125.2002. 01677.x 12392587 (Pubitemid 35334952)
32. AM Lefer B Campbell YK Shin, et al. 1999 Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts Circulation 100 2 178 184 1:CAS:528:DyaK1MXkvV2qtbg%3D 10402448
33. O Feron C Dessy JP Desager, et al. 2001 Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance Circulation 103 1 113 118 1:CAS:528:DC%2BD3MXhtFelsrs%3D 11136695
34. PY Liu YW Liu LJ Lin, et al. 2009 Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation Circulation 119 1 131 138 1:CAS:528:DC%2BD1cXhsFCmsr3K 10.1161/CIRCULATIONAHA.108.813311 19075102
35. M Kayikcioglu S Payzin O Yavuzgil, et al. 2003 Benefits of statin treatment in cardiac syndrome-X Eur Heart J 24 22 1999 2005 1:CAS:528: DC%2BD3sXovVehsb0%3D 10.1016/S0195-668X(03)00478-0 14613735 (Pubitemid 37420446)
36. CJ Pepine RD Anderson BL Sharaf, et al. 2010 Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study J Am Coll Cardiol 55 25 2825 2832 1:CAS:528:DC%2BC3cXps1ansLY%3D 10.1016/j.jacc.2010.01.054 20579539
37. MA Albert E Danielson N Rifai, et al. 2001 Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 1 64 70 1:CAS:528: DC%2BD3MXltleit74%3D 10.1001/jama.286.1.64 11434828
38. K Yasunari K Maeda M Minami, et al. 2001 HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress Arterioscler Thromb Vasc Biol 21 6 937 942 1:CAS:528:DC%2BD3MXksVakt78%3D 11397700
39. V Gaddam DY Li JL Mehta 2002 Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering J Cardiovasc Pharmacol Ther 7 4 247 253 1:CAS:528:DC%2BD3sXkslSmtw%3D%3D 10.1177/107424840200700408 12490971
40. TC Chou YF Lin WC Wu, et al. 2008 Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin Br J Pharmacol 153 6 1281 1287 1:CAS:528:DC%2BD1cXjtlelsbY%3D 10.1038/bjp.2008.19 18264124 (Pubitemid 351415513)
41. Meijer P, Wouters CW, van den Broek PH, et al. Upregulation of Ecto-5′-Nucleotidase by Rosuvastatin Increases the Vasodilator Response to Ischemia. Hypertension. 2010;Aug 2 [Epub ahead of print].
42. P Meijer WJ Oyen D Dekker, et al. 2009 Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection Arterioscler Thromb Vasc Biol 29 6 963 968 1:CAS:528:DC%2BD1MXlslCnsLg%3D 10.1161/ATVBAHA.108.179622 19359665
43. C Briguori G Visconti A Focaccio, et al. 2009 Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction J Am Coll Cardiol 54 23 2157 2163 1:CAS:528:DC%2BC3cXkvFOhsw%3D%3D 10.1016/j.jacc.2009.07.005 19664895
44. C Briguori A Colombo F Airoldi, et al. 2004 Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction Eur Heart J 25 20 1822 1828 1:CAS:528:DC%2BD2cXotlSmu7g%3D 10.1016/j.ehj.2004.07.017 15474697 (Pubitemid 39330233)
45. VA Mannacio D Iorio V De Amicis, et al. 2008 Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial J Thorac Cardiovasc Surg 136 6 1541 1548 10.1016/j.jtcvs.2008.06.038 19114204